gilteritinib-resistant FLT3 mutants don't bind gilteritinib

Stable Identifier
R-HSA-9702589
Type
Reaction [transition]
Species
Homo sapiens
Compartment
plasma membrane
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
gilteritinib-resistant FLT3 mutants don't bind gilteritinib
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

The following FLT3 mutants are resistant to inhibition by gilteritinib:

FLT3 F691L (partial: Mori et al, 2017; Tarver et al, 2020)
FLT3 F691I (partial: Mori et al, 2017)

Literature References
PubMed ID Title Journal Year
32040554 Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations

Tarver, TC, Hill, JE, Rahmat, L, Perl, AE, Bahceci, E, Mori, K, Smith, CC

Blood Adv 2020
28516360 Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia

Mori, M, Kaneko, N, Ueno, Y, Yamada, M, Tanaka, R, Saito, R, Shimada, I, Mori, K, Kuromitsu, S

Invest New Drugs 2017
Participants
Input
Participant Of
hasEvent
Normal reaction
FLT3 binds type I TKI (Homo sapiens)
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Rothfels, K  (2020-11-06)
Reviewed
Kazi, JU  (2020-11-06)
Created
Rothfels, K  (2020-10-01)
Cite Us!